Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Working Capital Changes (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other Working Capital Changes for 7 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 56.93% to $18.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.8 million, a 133.51% increase, with the full-year FY2025 number at $20.8 million, up 133.51% from a year prior.
  • Other Working Capital Changes was $18.8 million for Q4 2025 at Kymera Therapeutics, up from $4.5 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $58.2 million in Q4 2021 to a low of -$54.3 million in Q3 2021.
  • A 5-year average of $1.7 million and a median of $420000.0 in 2022 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 3953.96% in 2023; the steepest drop was 2156.13% in 2023.
  • Kymera Therapeutics' Other Working Capital Changes stood at $58.2 million in 2021, then crashed by 99.18% to $480000.0 in 2022, then surged by 3953.96% to $19.5 million in 2023, then surged by 123.7% to $43.5 million in 2024, then crashed by 56.93% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Other Working Capital Changes are $18.8 million (Q4 2025), $4.5 million (Q3 2025), and $360000.0 (Q2 2025).